CARB-X Application Round #3 goes live!

Dear All:

The wait is over — CARB-X has today released a call for new applications! The call has an interesting 2-round structure and you’ll need to study carefully both the press release and the supplemental details document to understand where your program would fit. Here’s my summary:

  • Round 1:
    • Submission window for Expressions of Interest: 22-29 March 2018
    • Scope: Restricted to new classes of direct-acting small molecule and large molecule antibacterials that have potential to cover the top 6 Gram-negative pathogen groups from the WHO and CDC priority listsA. baumannii (carbapenem-R), P. aeruginosa (carbapenem-R), Enterobacteriaceae (carbapenem-R and/or 3rd-gen ceph-R), Salmonellae spp. (fluoroquinolone-R), N. gonorrhoeae (3rd-gen ceph-R, fluoroquinolone-R), and Shigella spp. (fluoroquinolone-R).
  • Round 2:
    • Submission window for Expressions of Interest: 1-8 June 2018
    • Scope: Both direct- and indirect-acting therapeutics as well as vaccines, diagnostics and devices that meet certain criteria.
    • In terms of therapeutics, both novel and known classes are acceptable.

The very tight focus of Round #1 feels right to me … we really need to push hard at a global level on the creation of entirely novel classes of direct-acting agents. These will be rare but they are needed.

The scope of Round #2 is then broad and roughly comparable to the scope of prior CARB-X funding rounds.

With an announced portfolio of more than 20 projects and its search for both new accelerators and new staff, CARB-X continues to lead the charge against AMR. Exciting times! 

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top